Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Diagnostic Accuracy of Interferon Gamma-Induced Protein 10 mRNA Release Assay for Tuberculosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Multicenter evaluation of the QIAstat-Dx respiratory panel for detection of viruses and bacteria in nasopharyngeal swab specimens

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Update from a twelve-year nationwide fungaemia surveillance: increasing intrinsic and acquired resistance causes concern

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. PREVALENCE OF HUMAN PAPILLOMAVIRUS IN SELF-TAKEN SAMPLES FROM SCREENING NON-ATTENDERS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Dientamoeba fragilis - a Commensal in Children in Danish Day Care Centers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • F Bottari
  • M Sideri
  • C Gulmini
  • S Igidbashian
  • A Tricca
  • C Casadio
  • S Carinelli
  • S Boveri
  • D Ejegod
  • J Bonde
  • M T Sandri
Vis graf over relationer

Analytical and clinical performance validation is essential before introduction of a new human papillomavirus (HPV) assay into clinical practice. This study compares the new BD Onclarity HPV assay, which detects E6/E7 DNA from 14 high-risk HPV types, to the Hybrid Capture II (HC2) HPV DNA test, to concurrent cytology and histology results, in order to evaluate its performance in detecting high-grade cervical lesions. A population of 567 women, including 325 with ≥ASCUS (where ASCUS stands for atypical cells of undetermined significance) and any HC2 result and 242 with both negative cytology and negative HC2 results, were prospectively enrolled for the study. The overall agreement between Onclarity and HC2 was 94.6% (95% confidence intervals [CI], 92.3% to 96.2%). In this population with a high prevalence of disease, the relative sensitivities (versus adjudicated cervical intraepithelial neoplasia grades 2 and 3 [CIN2+] histology endpoints) of the Onclarity and HC2 tests were 95.2% (95% CI, 90.7% to 97.5%) and 96.9% (95% CI, 92.9% to 98.7%), respectively, and the relative specificities were 50.3% (95% CI, 43.2% to 57.4%) for BD and 40.8% (95% CI, 33.9%, 48.1%) for HC2. These results indicate that the BD Onclarity HPV assay has sensitivity comparable to that of the HC2 assay, with a trend to an increased specificity. Moreover, as Onclarity gives the chance to discriminate between the different genotypes, we calculated the genotype prevalence and the absolute risk of CIN2+: HPV 16 was the most prevalent genotype (19.8%) with an absolute risk of CIN2+ of 77.1%.

OriginalsprogEngelsk
TidsskriftJournal of Clinical Microbiology
Vol/bind53
Udgave nummer7
Sider (fra-til)2109-14
Antal sider6
ISSN0095-1137
DOI
StatusUdgivet - jul. 2015

Mest downloadede publikationer

Ingen data tilgængelig

ID: 45562415